NLRP1 and pancreatic adenocarcinoma: Multi‐omics analyses further reinforce the prospect of NLRP1 serving as a biomarker for drug sensitivity in pancreatic adenocarcinoma [57, 58] and head and neck squamous cell carcinoma [54].